摘要
目的 探究凝血酶冻干粉联合奥美拉唑在治疗消化道溃疡出血上的临床效果及对其纤维蛋白原水平变化的影响.方法 将永康医院收治的118例消化道溃疡出血的患者纳入本次研究,按照入院治疗的先后顺序将其分为观察组和对照组.对照组患者仅给予奥美拉唑等常规治疗;观察组患者则在此基础上联合凝血酶冻干粉进行治疗.对比2组患者的临床治疗效果,并于治疗前后比较2组患者的纤维蛋白原水平变化.结果 治疗后,观察组患者的总有效率为91.07%,对照组患者的总有效率为75.81%,2组比较差异有统计学意义(P〈0.05).治疗前,2组患者的纤维蛋白原水平比较无统计学意义.随着治疗的进行,2组患者的纤维蛋白原水平持续降低,但观察组患者的下降幅度明显大于对照组,差异比较有统计学意义(P〈0.05).结论 凝血酶冻干粉联合奥美拉唑在治疗消化道溃疡出血上效果显著,能够有效降低血液中的纤维蛋白原水平,止血迅速,且临床用药安全可靠,值得在临床上积极推广.
Objective To explore the Lyophilizing Thrombin Powder combined with omeprazole in the treatment of peptic ulcer hemorrhage on clinical effect and influence on the change of the original level of the fiber protein.Methods118 cases of peptic ulcer bleeding from Yongkang Hospital were enrolled in this study, according to the order of hospitalization will be divided into observation group and control group.The control group were only given omeprazole and other conventional treatment;patients in the observation group was combined with Lyophilizing Thrombin Powder for treatment.The clinical treatment effect were compared between the two groups before and after treatment, compared two groups of patients with changes in fibrinogen levels.ResultsAfter treatment, the total efficiency rate of observation group was 91.07%, the total effective rate of control group was 75.81%, there was significant difference between two groups (P〈0.05).Before treatment, two groups of patients with fibrinogen level was not statistically significant.With the treatment, the two groups of patients with fibrin the original level decreased, but the patients in the observation group decreased more significantly than the control group, the difference was statistically significant (P〈0.05).ConclusionLyophilizing Thrombin Powder combined with omeprazole in the treatment of peptic ulcer bleeding effect significantly, can effectively reduce blood fibrinogen level, hemostasis, and its clinical use is safe and reliable, and is worth to popularize in clinic.
作者
陈巧恩
陈成家
CHEN Qiao-en CHEN Cheng-jia(Department of Gastroenterology, Yongkang Hospital, Yongkang 321300 China)
出处
《中国生化药物杂志》
CAS
2017年第6期249-250,253,共3页
Chinese Journal of Biochemical Pharmaceutics